DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the PE ratio of Novelix Pharmaceuticals Ltd?

Novelix Pharmaceuticals Ltd has a price-to-earnings (PE) ratio of 78.5 in the Retail sector.

What is the market capitalisation of Novelix Pharmaceuticals Ltd?

Novelix Pharmaceuticals Ltd has a market capitalisation of approximately ₹201 crore.

Novelix Pharmaceuticals Ltd

536565·NSE·Retail

₹0.00▲ +0.00 (+0.00%)

Mkt Cap₹201 Cr

P/E78.50

Vol—

Day—

52W38–92

Trading suspended. Not a live price.

Retail · Pharmacy Retail

A steady, established business

O—H—L—PC—VWAP—VOL—

52W₹38.00

₹92.00

Snapshot

Key stats

Mkt Cap

₹201 Cr

P/E

78.50Expensive

P/B

3.06

ROE

8.00%Weak

ROCE

1.00%Weak

52W High / Low

₹92 / ₹38

Div Yield

0.00%

EPS

₹0.08

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

78.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

8.0%Weak

Above 15% is considered healthy for Indian equities

ROCE

1.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.09Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹201 Cr

P/B

3.06

EPS

₹0.08

Div Yield

—

What changed

Recent changes

Promoters+3.72% stake last quarter

What matters

News impact

Today

Trading activity

Delivery %—

Turnover—

Trades—

VWAP—

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+66.3%

+55.9%

10Y

+24.9%

Profit

—

10Y

—

EPS

—

10Y

+26.0%

Profile

Pros

Company is almost debt free.
Promoter holding has increased by 4.86% over last quarter.
Company's median sales growth is 42.1% of last 10 years
Company's working capital requirements have reduced from 222 days to 122 days

Watch-outs

Cons

Stock is trading at 3.17 times its book value
Though the company is reporting repeated profits, it is not paying out dividend
Company has a low return on equity of 5.12% over last 3 years.
Company has high debtors of 163 days.
Promoter holding has decreased over last 3 years: -12.6%

More Retail stocks · Pharmacy Retail

Explore Novelix Pharmaceuticals Ltd’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.